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Background: Blood biomarkers are needed to monitor anti-angiogenic treatments for cancer. The association of
blood levels of microRNAs (miRs) implicated in angiogenesis with circulating endothelial cells (CEC) and with
angiogenic proteins was examined in patients administered drugs with anti-angiogenic activity.
Methods: Blood was collected from patients with uveal melanoma enrolled on an adjuvant therapy trial in which
they were treated sequentially with dacarbazine and interferon-alfa-2b. Plasma levels of nine angioregulatory miRs,
miR-16, 20a, 106a, 125b, 126, 146a, 155, 199a, and 221, were determined by quantitative real time polymerase chain
reaction; CEC, by semi-automated immunomagnetic; and plasma angiogenic proteins, by enzyme linked
immunosorbent assays.
Results: Levels of miR-199a were positively correlated and miR-106a negatively correlated with CEC pre-therapy.
Decreases in miR-126 and miR-199a and increases in miR-16 and miR-106a were observed after interferon-alfa-2b,
but not after dacarbazine. CEC also increased after treatment with interferon but not after treatment with
dacarbazine. Levels of miRs did not correlate with levels of vascular endothelial growth factor, basic fibroblast
growth factor, and interleukin-8. Angiogenic proteins also did not change significantly with treatment.
Conclusions: Blood levels of specific angioregulatory miRs are associated with CEC, and changes in specific
angioregulatory miRs parallel increases in CEC after treatment with interferon-alfa-2b. Blood levels of specific
angioregulatory miRs are not associated with levels of angiogenic proteins. miRs warrant further evaluation as
blood biomarkers of angiogenesis.
Keywords: Biomarker, Tumor angiogenesis, Vascular endothelial growth factor, Basic fibroblast growth factors,
Interleukin-8, MelanomaBackground
A number of drugs with anti-angiogenic effects are in
common use to treat cancer, and a number are under in-
vestigation. Although many methods have been tested in
preclinical and clinical studies, there are no established
methods of serially monitoring patients receiving anti-
angiogenic therapies. Several studies have focused on
known protein mediators of angiogenic processes.* Correspondence: triozzp@ccf.org
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reproduction in any medium, provided the orChanges in blood levels of, e.g., vascular endothelial
growth factor (VEGF), basic fibroblast growth factors
(bFGF), and interleukin- (IL-) 8, have been observed in
response to anti-angiogenic drugs. The results have been
conflicting, due in part to the different clinical situations
investigated. Their use may also be confounded by
increases associated with tumor progression, and the
practical utility of using drug-induced changes in angior-
egulatory proteins as blood biomarkers remains to be
demonstrated [1].
Circulating endothelial cells (CEC) are mature endo-
thelial cells that have detached from the vessel wall andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ical trials have associated changes in CEC with outcome
to anti-angiogenic treatments. Increases in CEC were
associated with clinical benefit in studies in renal [2], pan-
creatic [3], and breast cancers [4] and gastrointestinal stro-
mal tumor [5]. In patients with solid tumors randomized
to anti-angiogenic drug combinations, CEC were lower in
patients without clinical benefit; of note, levels of VEGF
did not differ in these patients [6]. In contrast, in studies
in colon cancer [7] and in glioblastoma [8], an increase in
CEC was associated with a worse clinical outcome, and in
a study in breast cancer, a decrease in CEC was associated
with clinical response [9]. Still in others, including studies
in colon [10] renal [11], and hepatocellular cancers [12],
changes in CEC were not associated with clinical outcome.
Furthermore, tumor progression is accompanied by
increases in CEC [13].
Tumor angiogenesis has been shown to be regulated
by microRNAs (miRs), small noncoding RNAs that bind
to mRNAs, recruit a silencing complex, and block trans-
lation. miRs that can promote angiogenesis, including
miR-126, 155, 199a, and miRs of the 17–92 complex,
and miRs that can inhibit angiogenesis, including
miR-16, 106a, 125b, and 221, have been identified. These
miRs have been implicated in the regulation of a range
of target genes involved in angiogenesis, such as those
involved in response to hypoxia, production of angio-
genic proteins/growth factors, and endothelial cell prolif-
eration and migration [14]. miRs are very stable in blood
because of incorporation in microparticles and exo-
somes. Because of sensitive detection methods and their
low complexity, when compared to proteins and cells,
blood miRs are under investigation as cancer biomarkers
[15]. There is, however, little information regarding the
effects of drugs with anti-angiogenic effects on circulat-
ing miRs.
With the overall objective of developing blood biomar-
kers of angiogenesis, we examined the associations of
blood levels of miRs implicated in angiogenesis with those
of angiogenic proteins and CEC in patients with primary
uveal melanoma on systemic adjuvant therapy consisting
of low-dose dacarbazine followed by interferon-alfa-2b,
drugs with anti-angiogenic effects. Interferon-α has well-
documented inhibitory effects on endothelium and angio-
genic factors [16]. Dacarbazine, like temozolomide, is a
prodrug of the alkylating agent 5-[3-methyltriazen-1-yl]
imidazole-4-carboximide, which also has demonstrated in-
hibitory effects on endothelium and angiogenic factors
[17]. Increases in CEC have been observed in clinical trials
that included interferon-alfa-2b and temozolomide
[18,19]. In addition, the patients we evaluated did not have
clinically detectable cancer, which lessened the potential
impact on cancer burden on the biomarkers tested. The
sequential treatment program utilized, which improveddisease-free survival in resected, high-risk cutaneous mel-
anoma [20], also allowed for the comparison of an anti-
angiogenic chemical and an anti-angiogenic cytokine
within the same patient.Methods
Patients and treatment
This study was approved by Cleveland Clinic Institutional
Review Board and was in compliance with the Helsinki
Declaration. All subjects provided written informed con-
sent. The patients enrolled had a histocytologic diagnosis
of melanoma of the iris, ciliary body and/or choroid; high-
risk tumor cytogenetics (i.e., monosomy 3), adequate pri-
mary therapy (e.g., enucleation or brachytherapy); negative
imaging to eliminate distant disease; performance status
(ECOG) less than 2; and normal organ function. Patients
had to be entered within 56 days of completing primary
therapy. Dacarbazine was administered at 850 mg/m2
intravenously on day 1 and day 28. Interferon-alfa-2b was
administered at 3 million units three times a week sub-
cutaneously for 24 weeks beginning week 9. Patients were
pre-medicated with 650 mg acetaminophen prior to inter-
feron-alfa-2b. Blood for laboratory correlates was drawn
and analyzed week 1, prior to starting dacarbazine in 21
patients. Blood was also drawn and analyzed in 12 patients
at week 9, after dacarbazine and prior to starting inter-
feron; weeks 17, 25, and 33, on interferon; and at 6
months after therapy was discontinued.Circulating miRs
Total RNA was isolated from plasma using the miRNeasy
Mini Kit (Qiagen, Valencia, CA) according to the manu-
facturer’s instructions. Reverse transcription reactions
were performed using a TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA)
according to the manufacturer’s instructions. Quantita-
tive real-time polymerase chain reaction (qRT-PCR)
was performed using the reverse transcription reaction
product, TaqMan MicroRNA Assay kit, and TaqMan
Universal PCR Master Mix (Applied Biosystems)
according to the manufacturer’s instructions. TaqMan
MicroRNA Assay kits for human miRs were used. Reac-
tions were loaded onto a 96-well plate and run in dupli-
cate on an ABI 7500 Fast Real-Time PCR System
(Applied Biosystems). The reactions were incubated at
50°C for 20 seconds and 95°C for 10 minutes, followed
by 40 cycles of denaturation at 95°C for 15 seconds,
then 1 minute of annealing/extension at 60°C. The
ΔΔCT method was used to determine relative number
of copies (RQ) of miR. Data were normalized to a
C. elegans synthetic miR sequence, cel-miR-39 (Qiagen),












Figure 1 Box plots of anti- and pro-angiogenic miR levels prior
to starting treatment, n = 21. Horizontal lines represent the
median, the box represents the 25th and 75th percentiles, and
whiskers represent the minimum and maximum.
r = -0.43





































Figure 2 Correlations between miR-106a (top) and miR-199a
(bottom) levels and CEC prior to starting treatment, n = 21.
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Plasma VEGF, IL-8, and bFGF levels were measured using
enzyme linked immunosorbent assay kits (R&D Systems,
Minneapolis, MN) according to the instructions of the
manufacturer. Results are expressed as pg/ml.
CEC enumeration
The CellTracksW AutoPrepW System and the CellSpotterW
Analyzer II System (Veridex, LLC, Raritan, NJ) were used
to enumerate CEC, as has been described [21]. In brief,
4 ml of blood were used for immunomagnetic enrichment
using ferrofluids coupled to an anti-CD146 antibody. This
marker is present on endothelial cells, a subset of activated
T-lymphocytes, and melanoma cells. After enrichment, the
following reagents were added: the nuclear dye 4,6-
diamidino-2-phenylindole (DAPI), and fluorochrome-con-
jugated monoclonal antibodies: phycoerythrin-conjugated
CD105, which is present on endothelial cells, activated
monocytes, and pre-B-lymphocytes, and allophycocyanin-
conjugated CD45, a pan-leukocyte antigen included in
order to exclude hematopoietic cells from analysis. Analysis
was done using image cytometry, where CEC were defined
as being CD146+, DAPI+, CD105+ and CD45–. Results are
expressed as number of CEC per 4 ml blood.
Statistical analysis
Data are presented as means ± SEM. Differences were
evaluated using unpaired t tests, whereas variations be-
tween pre- and post-treatment samples were analyzed
using paired t tests. Spearman rank correlations were
used to summarize overall relationships. P <0.05 was
considered significant. All tests of statistical significance
were 2-sided and performed using SAS version 9.2 (SAS
Institute Inc, Cary, NC).
Results
Angioregulatory miRs
Blood was collected from patients with uveal melanoma en-
rolled on an adjuvant therapy trial in which they were trea-
ted sequentially with dacarbazine and interferon. All
patients had undergone primary therapy. All patients toler-
ated treatment, and all completed the program without
delays or dose modifications. All patients were disease-free
when evaluated 6 months after completion. Plasma levels
of nine miRs implicated in regulating angiogenesis were
quantified using qRT-PCR. All nine evaluated were measur-
able in plasma week 1, prior to starting therapy (Figure 1).
Levels of pro-angiogenic miRs did not differ from anti-
angiogenic. Levels of miR-199a were positively correlated
and levels of miR-106a were negatively correlated with
CEC levels pre-therapy (Figure 2). A negative correlation of
miR-221 (r = -0.40) with CEC did not reach the level of sig-
nificance (P < 0.09). None of the nine miRs tested were cor-
related with angiogenic protein levels. Plasma levels ofmiRs did not change at week 9, after two infusions of dacar-
bazine. At week 17, after eight week of interferon-alfa-2b,
levels of miR-126 and 199a decreased, and levels of miR-16
and 106a increased (Figure 3). The increase in miR-106a
persisted at day 25; changes in miR-16, 126, and 199a, did
not. At week 33 and at 6 months, levels of these miRs
returned to baseline. The correlation of levels of miR-199a
and 106a with CEC observed at baseline did not persist
during therapy, r = -0.28 and r = −0.24, respectively. Sig-
nificant changes in the levels of miR-20a, 125b, 146a, 155,
and 221 were not observed at any time point. Levels of




















Figure 3 Levels of miR-16, 106a, 126, and 199a of patients administered sequential dacarbazine and interferon-alfa-2b prior to starting
treatment (W1), at weeks (W) 9, 17, 25, 33, and at 6 months (M6) after completing treatments. Data represent means ± SEM;

























Figure 4 (A) Angiogenic protein levels and (B) CEC of patients
administered sequential dacarbazine and interferon-alfa-2b
prior to starting (W1) and at weeks (W) 9, 17, 25, 33 and 6
months (M6) after completing treatments. Data represent means
± SEM; n = 12. * = P <0.05 compared to W1.
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VEGF, bFGF, and IL-8 levels were at the same time points
that miR levels were determined. Although increases after
dacarbazine and decreases after interferon-alfa-2b were
observed in individual patients, significant changes in these
angiogenic proteins were not apparent at any time point
(Figure 4A). From 0 to 97 CEC (mean ± SD = 21 ± 18,
median = 15) are found in healthy volunteers, as quantified
with the semi-automated immunomagnetic technique used
[22]. CEC at week 1, prior to starting therapy, were within
this range in all patients. CEC did not change at week 9,
after two infusions of dacarbazine. At week 17, after eight
week of interferon-alfa-2b, CEC increased significantly.
These increases were maintained at week 25, after 16 weeks
of interferon, and at week 33, after 24 weeks of interferon.
The decreases at weeks 25 and 33 compared to week 17
did not reach the level of significance. After being off treat-
ment for 6 months, CEC levels returned to baseline
(Figure 4B). Levels of CEC and angiogenic proteins did not
correlate prior, during, or after therapy.
Discussion
Blood markers are needed to help guide anti-angiogenic
therapy. miRs are emerging as important biomarkers,
and several miRs have been implicated in regulating
tumor angiogenesis [14]. Whether measurement of these
miRs in the circulation may be useful clinically has not
been established. We found that plasma levels of specific
angioregulatory miRs may have utility. There was a posi-
tive correlation between levels of the pro-angiogenic
miR-199a and a negative correlation between the anti-
angiogenic miR-106a with CEC, both moderate, in
patients with uveal melanoma prior to receiving systemic
adjuvant therapy. miR-199a promotes the proliferation of
endothelial cells though effects on caveolin-2 [23].
miR-106a, a paralog of miRs of the miR-17-92 cluster, is
upregulated during hypoxia and is predicted to targetVEGF [24,25]. With treatment with sequential dacarbazine
and interferon-alfa-2b, drugs with anti-angiogenic activ-
ities, decreases in miR-199a and in another pro-
angiogenic miR, miR-126, and increases in miR-106 and
another anti-angiogenic miR, miR-16, were observed.
miR-126, an endothelial cell-restricted miR, regulates vas-
cular integrity and angiogenesis. It enhances the actions of
VEGF and bFGF by repressing the Spred-1, an inhibitor of
Triozzi et al. Journal of Translational Medicine 2012, 10:241 Page 5 of 7
http://www.translational-medicine.com/content/10/1/241angiogenic signaling [26]. miR-16 is implicated in suppres-
sing VEGF and bFGF [27]. miR-16 and 199a have been
shown to be produced by human endothelial cells [28].
miR-106a and 199a, as well as miR-146, were among seven
miRs found to be increased in the neo-vascularization
response to ischemia within the eye in a mouse model [29].
Correlations and changes were not observed in other
angioregulatory miRs. These included miR-20a, a pro-
angiogenic miR in the 17–92 cluster that represses
thrombospondin-1 and connective tissue growth factor
[30]; miR-155, which is pro-angiogenic through effects on
angiotensin signaling [31], miR-125b, which is anti-
angiogenic through effects on placenta growth factor [32];
miR-146a, which is anti-angiogenic though effects of
NFκB and suppression of IL-8 and epidermal growth fac-
tor receptor signaling [33]; and miR-221, which impairs
stem-cell-factor-induced angiogenesis [34]. miR-20a and
221 have also been shown to be produced by human
endothelial cells [28]. The relationship between a miR and
a target is not exclusive, and depending on what genes are
suppressed, a given miR can have either a positive or nega-
tive role in the regulation of angiogenesis. Although a
member of the pro-angiogenic miR-17-92 cluster, miR-20a
can also suppress angiogenesis by suppressing VEGF [25].
miR-199a also affects hypoxia-inducible factor 1 [35] and
is predicted to target VEGF [25]. Furthermore, all the
miRs tested target multiple genes not directly or indirectly
involved in angiogenesis, and several miRs, such as
miR-20a and 106a, have been reported to be upregulated
in uveal melanoma [36].
Correlations were not observed between levels of miRs
and levels of VEGF, bFGF, and IL-8, angiogenic proteins
that have been shown to be produced by uveal melanoma
[37]. No patient had clinical evidence of cancer at any
time during the assessments. In lung cancer, tumor
miR-20 was significantly associated with tumor VEGF, and
tumor miR-155, with tumor bFGF [38,39]. We also did
not observe consistent effects of treatment with dacarba-
zine or interferon-alfa-2b on the levels of angiogenic pro-
teins. Although changes in the blood levels of angiogenic
proteins have been observed in patients administered a
variety of anti-angiogenic treatments, they have not been
consistent [1]. In one study in patients with cutaneous
melanoma administered interferon-alfa-2b, IL-8 levels
increased while VEGF and bFGF did not change [40]; in
another, levels of VEGF decreased, while levels of bFGF
and IL-8 did not change [41].
Significant changes in levels of miRs and also of CEC
were observed after treatment with interferon-alfa-2b, but
not after treatment with dacarbazine. In contrast to inter-
feron-alfa-2b, the dose and scheduling of dacarbazine were
likely not optimal to demonstrate angioregulatory effects,
more usually achieved with more repetitive, i.e., “metro-
nomic,” dosing [17]. The increases in CEC were mostapparent when assayed at the week 17 time point, after
8 weeks of interferon, and persisted. The increases in pro-
angiogenic and the decreases in anti-angiogenic miRs
observed also were most apparent at week 17, but were
transient. Interferon-α, which has immune modulatory,
antiproliferative, and antiviral effects, has been shown to in-
crease specific miRs by melanoma cells [42]. Whether
angioregulatory miRs are modulated has not been reported.
Increases in several miRs were observed in patients with
chronic hepatitis C virus infection treated with pegylated
interferon-alfa-2b but did not correlate with viral load or
liver function tests [43].
Whether blood levels of the miRs studied as well other
miRs may be useful in monitoring anti-angiogenic ther-
apy merits further investigation. The relative prognostic
and predictive value of blood miRs compared to CEC,
measurement of which has yielded conflicting results,
also merits further evaluation. Of note, levels of angiore-
gulatory miRs during treatment were not significantly
correlated with CEC. The clinical situation, the anti-
angiogenic approach, and the molecular targets will need
to be considered. Given the complexity of the angiogenic
process, a combination of several types of biomarkers
may be necessary. Studies wherein miR levels and CEC
are being assessed in conjunction with liver function
tests and imaging studies as part of systemic surveillance
for metastases in patients with uveal melanoma are
underway.Conclusions
Measuring blood levels of specific miRs implicated in
angiogenesis, including miR-16, 106a, 126, and 199a, may
have clinical utility in monitoring anti-angiogenic therapy
in patients with cancer.
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